Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Mitochondria-dependent phase separation of disease-relevant proteins drives pathological features of age-related macular degeneration
Nilsa La Cunza, … , Kimberly A. Toops, Aparna Lakkaraju
Nilsa La Cunza, … , Kimberly A. Toops, Aparna Lakkaraju
Published April 6, 2021
Citation Information: JCI Insight. 2021;6(9):e142254. https://doi.org/10.1172/jci.insight.142254.
View: Text | PDF
Research Article Ophthalmology

Mitochondria-dependent phase separation of disease-relevant proteins drives pathological features of age-related macular degeneration

  • Text
  • PDF
Abstract

Age-related macular degeneration (AMD) damages the retinal pigment epithelium (RPE), the tissue that safeguards photoreceptor health, leading to irreversible vision loss. Polymorphisms in cholesterol and complement genes are implicated in AMD, yet mechanisms linking risk variants to RPE injury remain unclear. We sought to determine how allelic variants in the apolipoprotein E cholesterol transporter modulate RPE homeostasis and function. Using live-cell imaging, we show that inefficient cholesterol transport by the AMD risk-associated ApoE2 increases RPE ceramide, leading to autophagic defects and complement-mediated mitochondrial damage. Mitochondrial injury drives redox state–sensitive cysteine-mediated phase separation of ApoE2, forming biomolecular condensates that could nucleate drusen. The protective ApoE4 isoform lacks these cysteines and is resistant to phase separation and condensate formation. In Abca–/– Stargardt macular degeneration mice, mitochondrial dysfunction induces liquid-liquid phase separation of p62/SQSTM1, a multifunctional protein that regulates autophagy. Drugs that decrease RPE cholesterol or ceramide prevent mitochondrial injury and phase separation in vitro and in vivo. In AMD donor RPE, mitochondrial fragmentation correlates with ApoE and p62 condensates. Our studies demonstrate that major AMD genetic and biological risk pathways converge upon RPE mitochondria, and identify mitochondrial stress-mediated protein phase separation as an important pathogenic mechanism and promising therapeutic target in AMD.

Authors

Nilsa La Cunza, Li Xuan Tan, Thushara Thamban, Colin J. Germer, Gurugirijha Rathnasamy, Kimberly A. Toops, Aparna Lakkaraju

×

Figure 5

Mitochondrial injury drives redox-mediated phase separation of ApoE2 and ApoE3.

Options: View larger image (or click on image) Download as PowerPoint
Mitochondrial injury drives redox-mediated phase separation of ApoE2 and...
(A) Percentage of ApoE condensates with volumes greater than 0.6 μm3 in RPE expressing ApoE2, ApoE3, or ApoE4 and treated with or without A2E or NHS. (B) IUPRED2A disorder plots for human ApoE2, ApoE3, and ApoE4. Redox state–dependent order-disorder transitions are depicted by the pink shaded area. Note increased disorder corresponding to cysteines at 112 and 158 in ApoE2 and at 112 in ApoE3. (C) Frequency distribution of condensate volumes in ApoE2-expressing RPE with A2E exposed to NHS and treated with simvastatin (5 μM, 16 h), T0901317 (1 μM, 16 h), or desipramine (10 μM, 3 h). Mean ± SEM, *P < 0.05, **P < 0.005, ***P < 0.0001. n = 15–29 cells per condition; 1-way ANOVA with Bonferroni’s posttest. See also Supplemental Figure 4.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts